2. GPCR/G Protein
  3. GLP Receptor GCGR
  4. TPM003

TPM003 (TG062) is a triple agonist of GLP-1R, GIPR and GCGR, with EC50 values of 33.9, 12.5 and 92.9 pM, respectively. TPM003 suppresses appetite, regulates blood glucose, enhances insulin sensitivity, reduces gastrointestinal intolerance, promotes hepatic lipid mobilization and increases energy expenditure. TPM003 induces weight loss, improves metabolic parameters, reverses hepatic steatosis and optimizes liver function markers. TPM003 is applicable for research on obesity and non-alcoholic steatohepatitis.

For research use only. We do not sell to patients.

TPM003

TPM003 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

TPM003 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TPM003 (TG062) is a triple agonist of GLP-1R, GIPR and GCGR, with EC50 values of 33.9, 12.5 and 92.9 pM, respectively. TPM003 suppresses appetite, regulates blood glucose, enhances insulin sensitivity, reduces gastrointestinal intolerance, promotes hepatic lipid mobilization and increases energy expenditure. TPM003 induces weight loss, improves metabolic parameters, reverses hepatic steatosis and optimizes liver function markers. TPM003 is applicable for research on obesity and non-alcoholic steatohepatitis[1].

Parmacokinetics
Species Dose Route T1/2 AUC0-inf AUC0-t Cmax Tmax F
Rat[1] 1.0 mg/kg i.v. 21.5 h 289.2 μg·h/mL 265.3 μg·h/mL / / /
Rat[1] 3.0 mg/kg s.c. 26.4 h 570.3 μg·h/mL 410.5 μg·h/mL 8.2 μg/mL 24 h 50.9 %
Cynomolgus Monkey[1] 0.2 mg/kg i.v. 83.3 h 302.1 μg·h/mL 277.6 μg·h/mL / / /
Cynomolgus Monkey[1] 0.2 mg/kg s.c. 97.2 h 228.9 μg·h/mL 199.0 μg·h/mL 1.8 μg/mL 18 h 75.7 %
Pig[1] 0.16 mg/kg i.v. 101.9 h 142.9 μg·h/mL 140.8 μg·h/mL / / /
Pig[1] 0.16 mg/kg s.c. 129.0 h 174.9 μg·h/mL 170.4 μg·h/mL 1.0 μg/mL 32 h 122.4 %
In Vivo

TPM003 (3-30 nmol/kg; s.c.; single administration) produces dose-dependent, sustained reductions in body weight, food intake, and postprandial blood glucose in lean male C57BL/6J mice[1].
TPM003 (10 nmol/kg; s.c.; single administration) exerts a sustained maximal weight loss effect in high-fat diet-induced obese male C57BL/6J mice[1].
TPM003 (10 nmol/kg; s.c.; once every 3 days for 21 days) induces a 30% reduction in body weight, potent suppression of food intake, and enhanced hepatic lipid clearance in high-fat diet-induced obese male C57BL/6J mice[1].
TPM003 (10 nmol/kg; s.c.; once daily or once every three days for 8 weeks) induces significant body weight loss and antifibrotic effects in mice induced by high-fat diet and CCl4[1].
TPM003 (1.0-3.0 mg/kg; s.c.; twice weekly for 4 weeks) induces reversible transient reductions in food intake and body weight in both male and female SD rats, with no serious adverse reactions[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6J (male, 8−10 weeks old)[1]
Dosage: 3 nmol/kg; 10 nmol/kg; 30 nmol/kg
Administration: s.c.; single dose
Result: Induced dose-dependent reductions in body weight, cumulative food intake, and fed blood glucose levels, with maximal effects within 96 hours post dosing.
Sustained body weight reduction effects until day 4 at 30 nmol/kg, when values returned to baseline.
Animal Model: C57BL/6J (male, high-fat diet-induced obesity)[1]
Dosage: 10 nmol/kg
Administration: s.c.; single dose
Result: Induced pronounced reductions in body weight, cumulative food intake, and blood glucose levels within 1−3 days post injection.
Produced a greater maximal weight reduction than retatrutide, with effects sustained without early rebound (unlike tirzepatide, which showed rebound starting at day 4).
Animal Model: C57BL/6J (male, high-fat diet-induced obesity)[1]
Dosage: 10 nmol/kg
Administration: s.c.; every 3 days; 21 days
Result: Achieved approximately 30% body weight reduction over the 21-day treatment period, with cumulative food intake suppressed to levels lower than tirzepatide-treated mice.
Reduced fasting blood glucose, plasma insulin, plasma alanine aminotransferase (ALT), blood triglycerides (TG), blood total cholesterol (TC), liver TG, and liver TC to levels approaching lean control values.
Showed the most substantial clearance of hepatic lipid droplets compared to retatrutide and tirzepatide via Oil Red O staining.
Animal Model: C57BL/6J (male, high-fat diet + carbon tetrachloride-induced NASH)[1]
Dosage: 10 nmol/kg
Administration: s.c.; daily; 8 weeks
Result: Produced a greater reduction in body weight compared to tirzepatide, reduced liver weight to levels approaching lean control values, and significantly decreased hepatic collagen deposition via Masson’s trichrome staining.
Induced significant reductions in key fibrosis markers: α-smooth muscle actin (α-SMA), fibronectin, and collagen type-I α-1 chain (COL1A1), with a significantly greater reduction in α-SMA expression compared to tirzepatide.
Animal Model: C57BL/6J (male, Gubra Amylin NASH diet-induced NASH)[1]
Dosage: 10 nmol/kg
Administration: s.c.; every 3 days; 8 weeks
Result: Induced progressive, sustained body weight loss throughout the 8-week period (with no rebound, unlike retatrutide which showed partial rebound after week 3).
Significantly reduced the NAFLD Activity Score (NAS) compared to both retatrutide and tirzepatide, particularly in steatosis and hepatocellular ballooning components.
Reduced hepatic collagen deposition, COL1A1, and α-SMA expression, indicating robust suppression of hepatic fibrosis and inflammation.
Animal Model: Sprague-Dawley (male, female, 8−10 weeks old)[1]
Dosage: 1.0 mg/kg; 3.0 mg/kg
Administration: s.c.; twice weekly; 4 weeks
Result: Induced transient reductions in food intake and body weight, with occasional emesis and mild diarrhea in a subset of animals; all effects were reversible upon treatment cessation.
No mortality, severe adverse events, overt serum biochemical pathological changes, or abnormal histological findings in key organs (thymus, spleen, mesenteric lymph nodes) were observed.
Molecular Weight

5196.91

Formula

C238H370FN51O73S2
SMILES

O=C([C@@H](N)CC1=CC=C(C=C1)O)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@](CC)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NC(C)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N2CCC[C@H]2C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N3CCC[C@H]3C(N4CCC[C@H]4C(N5CCC[C@H]5C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CSC6)=O)CC(C)C)=O)CC(C)C)=O)CC7=CC=C(O)C=C7)=O)CCC(O)=O)=O)[C@H](CC)C)=O)CC8=CC=CC=C8)=O)CSCC(NCCN(C(CCC(NCCOCCOCC(NCCOCCOCC(NCCCC[C@@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)CCNC6=O)=O)=O)C)=O)CCC(N)=O)=O)C)=O)CCCCNC(C)=O)=O)CCCCN)=O)CC(O)=O)=O)CC(C)C)=O)C)=O)[C@H](CC)C)=O)CO)=O)CC9=CC=C(O)C=C9)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC%10=C(C=CC=C%10)F)=O)[C@@H](C)O)=O)=O)CCC(N)=O)=O)C
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

TPM003 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TPM003TG062TPM 003TPM-003TG 062TG-062GLP ReceptorGCGRGlucagon ReceptorHEK293 cellsnonalcoholic steatohepatitisobesityGIPRSD ratsC57BL/6J miceinsulin sensitivityGLP-1Rhepatic steatosisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TPM003
Cat. No.:
HY-181709
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.